ClinicalTrials.gg
RecruitingNCT03071289Updated Jul 14, 2017

A Trial Comparing Observation With Radiation on Pelvic Lymphocysts After Radical Hysterectomy of Cervical Cancer

A Phase 3 interventional study of Radiation Method B and Cisplatin in Cervical Cancer, Lymphocyst and Radiation Therapy, sponsored by Sun Yat-sen University. Recruiting at 8 sites in China. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-07-14.

Sponsored by Sun Yat-sen University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Started Jun 2017; still recruiting 9 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
540
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Uterine Cervical Neoplasms by Sun Yat-sen University — 7 open to participants now, 9 under way, 3 of them phase 3. Uterine Cervical Neoplasms · Sun Yat-sen University.

Planned enrollment
4th of 17
540 · median 108
Started
2017
the only one that year
Phase 3
6 of 18
3 open now
Registered
6th of 18
by date

Among the 18 studies in Uterine Cervical Neoplasms by Sun Yat-sen University, this one is the 4th largest by planned enrollment of the 17 interventional ones that give a count, is the only one that started in 2017, is one of 6 in phase 3, and was the 6th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

7 of the 18 studies in Uterine Cervical Neoplasms by Sun Yat-sen University are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Uterine Cervical Neoplasms by Sun Yat-sen University, or all of them as a file.
02

Study summary

Cervical cancer of early stage is treated mainly by radical resection and (or) radiotherapy. And pelvic lymphocyst is one of the most common adverse events of radical resection. The aim of this study is to compare observation with radiation on pelvic lymphocyst of cervical cancer patients after radical resection, for incidence of adverse events and local recurrence rate.

Read the detailed description
  1. Background

    Cervical Cancer is one of the most common malignant tumors of Chinese females. The early stage diseases (Stage Ia, Ib and IIa1) is treated mainly by radical resection and (or) radiotherapy. And pelvic lymphocyst is one of the most common adverse events (incidence 18-35%) of radical resection. When adjuvant radiotherapy (ART) is performed, lymphocyst is included in the clinical target volume (CTV) with a dose of 45-50Gy, in most hospitals of China. However, there is no pathologic and clinical evidence that lymphocyst is associated with local recurrence. However, inclusion of lymphocyst might enlarge CTV and increase irradiation dose of organs at risk (OARs) such as small intestine and kidneys.

  2. Objective

    The aim of this study is to compare observation with radiation on pelvic lymphocyst of cervical cancer patients after radical resection, for incidence of adverse events and local recurrence rate.

  3. Patients and methods

A patient will be enrolled when patient have:

  1. pathologically diagnosed cervical cancer;
  2. Stage I-II diseases (FIGO system ver. 2014);
  3. treated with radical resection;
  4. need of ART according to NCCN guidelines ver. 2016v2.

Randomization is performed to divide the patients into the control group (Group A) and the experimental group (Group B). In Group A, the CTV includes all the lymphocyst. But in Group B, the CTV is delineated according to the lymph drainage pathway (not all the lymphocyst included). ART is performed with a dose of 60Gy to the gross tumor volume, and 45Gy to the CTV. Chemotherapy is given concurrently with cisplatin 30mg/m2 every week regimen. The Grade 3/4 adverse events (CTCAE criteria ver. 4.03) and the 5-year local-recurrence-free survival of the 2 groups are compared after 5-year follow-up with an interval of 3 months.

03

Conditions studied

  • Cervical Cancer
  • Lymphocyst
  • Radiation Therapy
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with pathological diagnosed cervical cancer and treated with radical resection
  • Stage I-II diseases (FIGO system ver. 2014)
  • Performance Scores ≥ 80 and expected survival ≥ 3 months
  • Pelvic MRI or CT indicate existence of lymphocyst
  • Need of radiotherapy according to NCCN guidelines ver. 2016v2 (SEDLIS criteria)

Exclusion criteria

Exclusion Criteria:

  • Patients with distant before or during radiotherapy
  • Severe dysfunction of heart, lung, liver, kidney or hematopoietic system
  • Severe neurological, mental or endocrine diseases
  • History of other
  • Prior chemotherapy, radiotherapy or application of monoclonal antibodies
  • Patients participated in clinical trials of other drugs within last 3 months
  • Pregnant or lactating women
  • Those who are considered by the researchers unsuitable to participate
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
540 participants (estimated)

Study arms

  • Active comparator
    The control group (Group A)

    In Group A, adjuvant radio-chemotherapy is applied. The radiotherapy is performed according to Radiation Method A. The regimen of chemotherapy is cisplatin 30mg/m2 every week.

    Drug: Cisplatin · Radiation: Radiation Method A

  • Experimental
    The experiment group (Group B)

    In Group B, adjuvant radio-chemotherapy is applied. The radiotherapy is performed according to Radiation Method B. The regimen of chemotherapy is cisplatin 30mg/m2 every week.

    Radiation: Radiation Method B · Drug: Cisplatin

Interventions

  • RadiationRadiation Method B

    The gross tumor volume (GTV) is the residual lesion after radical resection and given a dose of 60Gy. The clinical target volume (CTV) is delineated according to the lymph drainage pathway and included all the lymphocyst. The CTV is given a dose of 45Gy.

  • The regimen of chemotherapy is cisplatin 30mg/m2 every week.

  • RadiationRadiation Method A

    The gross tumor volume (GTV) is the residual lesion after radical resection and given a dose of 60Gy. The clinical target volume (CTV) is delineated according to the lymph drainage pathway and given a dose of 45Gy.

06

What researchers measure

Primary outcomes

  1. 5-year local-recurrence-free survival (5y-LRFS)

    Percentage of patients in a treatment group who are alive without local recurrence for a 5-year period of follow-up after the date of radiotherapy completion

    Time frame: 5 years after the date of radiotherapy completion

Secondary outcomes

  1. Incidence of grade 3/4 adverse event

    Incidence of patients in a treatment group who manifest a specific adverse event (such as myelosuppression) of grade 3/4. Incidence is calculated for each adverse event respectively and severity is evaluated on basis of Common Terminology Criteria for Adverse Events (CTCAE) criteria ver. 4.03.

    Time frame: Once a week during therapy, up to 5 years after the date of radiotherapy completion

  2. 5-year overall survival (5y-OS)

    Percentage of patients in a treatment group who are alive for a 5-year period of follow-up after the date of radiotherapy completion

    Time frame: 5 years after the date of radiotherapy completion

07

Study locations

1 of 8 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2017 (actual). Primary completion is estimated for Mar 2025, 93 months after the start.

Of 53 non-industry phase 3 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 80 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 107. This study's planned 93 months is above that.

Counting every sponsor, half of 99 studies reached it within 55 months; a quarter within 24 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2017
First posted
Mar 6, 2017
StartActual
Jun 1, 2017
Primary completionEst.
Mar 31, 2025
CompletionEst.
Mar 31, 2025
Last update
Jul 14, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03071289
Responsible party
Wei-jun Ye (Professor, Sun Yat-sen University) — Principal investigator
First posted
Mar 6, 2017
Start date
Jun 1, 2017
Primary completion
Mar 31, 2025 (estimated)
Completion
Mar 31, 2025 (estimated)
Last update
Jul 14, 2017

Study contacts

Wei-jun Ye, M.D
Contact
yewj@sysucc.org.cn
86-13538799871
Hui Chang, M.D
Contact
changhui@sysucc.org.cn
86-13480295989
Wei-jun Ye, M.D
principal investigator · Sun Yat-sen University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion